Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4066434.
LY4066434 · 1 trial · 5 indications
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY4066434 Monotherapy Dose Escalation | EXPERIMENTAL | Escalating doses of LY4066434 administered orally. |
| LY4066434 Dose Optimization | EXPERIMENTAL | LY4066434 administered orally either alone or with another investigational agent. |
| Name | Type | Description |
|---|---|---|
| LY4066434. | DRUG | Administered orally. |
| Cetuximab | DRUG | Administered intravenously. |
| Nab paclitaxel | DRUG | Administered intravenously. |
| Gemcitabine | DRUG | Administered intravenously. |
| Oxaliplatin | DRUG | Administered intravenously. |
| Leucovorin | DRUG | Administered intravenously. |
| Irinotecan | DRUG | Administered intravenously. |
| 5Fluorouracil | DRUG | Administered intravenously. |
| Carboplatin | DRUG | Administered intravenously. |
| Cisplatin | DRUG | Administered intravenously. |
| Pemetrexed | DRUG | Administered intravenously. |
| Pembrolizumab | DRUG | Administered intravenously. |
Inclusion Criteria: * Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA * Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer * Have measurable disease per RECIST 1.1 * H...
LY4066434 is an investigational small molecule being developed for pancreatic ductal adenocarcinoma. It is also being studied in non-small cell lung cancer, colorectal cancer, and advanced or metastatic solid tumors. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY4066434 targets KRAS, a gene that is frequently mutated in various cancers. As a pan-KRAS inhibitor, it is designed to act on multiple KRAS mutations. The drug is being evaluated in patients with KRAS mutant solid tumors, including pancreatic ductal adenocarcinoma.
LY4066434 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with KRAS mutant solid tumors.
LY4066434 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy.
LY4066434 is being studied in a Phase 1 clinical trial with the identifier NCT06607185. This trial is titled 'A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors' and is enrolling approximately 750 participants across multiple countries, including the United States, Belgium, France, Germany, Italy, Japan, Spain, and Taiwan.
LY4066434 is a distinct investigational drug developed by Eli Lilly. It is a pan-KRAS inhibitor, meaning it targets multiple KRAS mutations. While other KRAS inhibitors exist, LY4066434 is a unique compound being evaluated in its own clinical trial for KRAS mutant solid tumors.